Skip to main content

Alkermes Value Stock - Dividend - Research Selection

Alkermes

ISIN: IE00B56GVS15 , WKN: A1JKVH

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company\'s marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

2025-04-01
Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH – chronic, neurological disorders characterized by excessive daytime sleepiness.

Alkermes plc - New National Survey of Healthcare Providers Offers Insights into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

2025-03-28
DUBLIN - People living with schizophrenia or bipolar I disorder often face long and complex diagnostic and treatment journeys.Results from a newly completed survey designed to better understand the...

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

2025-03-27
People living with schizophrenia or bipolar I disorder (BDI) often face long and complex diagnostic and treatment journeys. Results from a newly completed survey designed to better understand the perspectives of healthcare providers on patients' treatment experiences and outcomes indicated that providers often prioritize approaches that support long-term symptom control, treatment consistency and quality of life considerations. This research was conducted online in the U.S. in September 2024 by

Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?

2025-03-25
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.

GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait

2025-03-22
GE Aerospace has formed a flat base, one of several stocks with strong relative strength near buy points and with relatively low volatility.

Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points

2025-03-17
On St. Patrick's Day, PDD Holdings and Aon lead five stocks near buy points that are at least a "little Irish."

Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?

2025-03-14
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment?

2025-03-14
We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a look at where Alkermes plc (NASDAQ:ALKS) stands against other best healthcare stocks for long-term investment. Rising Healthcare Costs and the Impact of Tariffs on the US Industry In the US, healthcare expenditures and […]

Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years

2025-03-14
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says

2025-03-13
Alkermes (ALKS) is facing "significant" near-term headwinds to its existing franchises and royalties